| Literature DB >> 28642748 |
Muhammad Miftahussurur1,2,3, Iswan A Nusi3, David Y Graham1, Yoshio Yamaoka1,2.
Abstract
The hygiene hypothesis links environmental and microbial exposures in early life to the prevalence of atopy, allergy, and asthma. Helicobacter pylori infection is typically acquired in childhood and acquisition of the infection is associated with poor household hygiene. Some population surveys have shown an inverse association between H. pylori infection and atopy, allergy, and asthma leading to the suggestion that H. pylori infection may be protective against disease; others consider it simply a biomarker for poor household hygiene. We review the relevant surveys, cohort studies, meta-analyses, and studies testing the protective hypothesis. Overall, the results of surveys and cohort studies are inconsistent, whereas meta-analyses show a significant but weak inverse correlation. In contrast, studies directly testing the protection hypothesis in relation to asthma in populations with poor hygiene and low H. pylori prevalence failed to confirm a protective effect. H. pylori is a major cause of human disease including chronic gastritis, peptic ulcer, and gastric malignancies. H. pylori infections most likely serve as a biomarker for poor hygienic conditions in childhood. We conclude that while synergistic interactions between environmental factors in childhood are important determinants of the pathogenesis of atopy, allergy, and asthma; H. pylori is inversely related to good hygiene and thus it's presence serves as a biomarker rather than for a specific prevention role for H. pylori or H. pylori antigens.Entities:
Keywords: Helicobacter pylori; allergy; asthma; atopy; hygiene hypothesis
Year: 2017 PMID: 28642748 PMCID: PMC5462935 DOI: 10.3389/fmicb.2017.01034
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Association between H. pylori and atopy, allergy, and asthma in cross-sectional studies.
| 1 | Kosunen | 2002 | 1973 | Finland | (15–54) | IgG and IgA | IgE | 16/147 (10.9) | 20/179 (11.2) | 0.9340 |
| 1994 | 3/59 (5.1) | 54/260 (20.8) | 0.0095 | |||||||
| 2 | Linneberg | 2003 | 1990–1991 | Denmark | (15–69) | IgG | IgE | 75/273 (27.5) | 323/824 (39.2) | <0.001 |
| Allergic rhinitis by questionnaire | 48/271 (17.7) | 236/822 (28.7) | <0.001 | |||||||
| 3 | Cullinan | 2003 | 1198–1999 | England | 28 | IgG | Skin prick test | 53/151 (35.0) | 278/745 (37.0) | 0.52 |
| 4 | McCune | 2003 | N/A | England | (20–59) | Urea breath test | Atopy by questionnaire | 85/1079 (7.9) | 235/2165 (10.9) | 0.007 |
| 5 | Jarvis | 2004 | 1992–1993 | England | (20–44) | IgG | Wheeze by questionnaire | 60/208 (28.9) | 167/613 (27.2) | 0.64 |
| Waking with cough by questionnaire | 62/208 (30.0) | 190/613 (31.0) | 0.21 | |||||||
| Hay fever by questionnaire | 60/208 (28.9) | 181/613 (29.6) | 0.95 | |||||||
| IgE | 83/208 (39.9) | 230/613 (37.6) | 0.43 | |||||||
| 6 | Radon | 2004 | 2002 | Germany | (18–44) | IgG | IgE | 18/91 (19.8) | 50/230 (21.7) | 0.814 |
| 7 | Pessi | 2004 | N/A | Finland | >30 | IgG | Asthma by physician | 115/245 (46.9) | 205/405 (50.6) | 0.370 |
| 8 | von Hertzen | 2005 | 1997–1998 | Finland | 25–54 | IgG | Skin prick test | 62/268 (23.1) | 141/507 (27.8) | 0.526 |
| Russia | 25–54 | IgG | Skin prick test | 78/90 (86.5) | 280/297 (94.3) | 0.011 | ||||
| 9 | Jun | 2006 | 2005–2005 | China | 50.5 | IgG | Chronic bronchitis | 40/46 (86.9) | 29/48 (60.4) | <0.01 |
| 10 | Chen | 2007 | 1998–1994 | United States | 43.0 | IgG | Self-reported asthma (current) | 169/3,720 (4.5) | 196/3,943 (5.0) | 0.409 |
| Self-reported asthma (lifetime) | 229/3,720 (6.2) | 296/3,943 (7.5) | 0.022 | |||||||
| Self-reported allergic rhinitis (current) | 236/3,720 (6.3) | 380/3,943 (9.6) | <0.001 | |||||||
| Self-reported allergic rhinitis (lifetime) | 278/3,720 (7.5) | 439/3,943 (11.1) | <0.001 | |||||||
| Self-reported allergic symptoms | 1,935/3,720 (52.0) | 2,398/3,943 (60.8) | <0.001 | |||||||
| 11 | Seiskari | 2007 | 1994, 1997–1999 | Finland, Russia | 11.4 (7–15) | IgG | IgE | 9/194 (4.6) | 8/72 (11.1) | 0.055 |
| 12 | Chen | 2008 | 1999–2000 | United States | (14–49) | IgG | Asthma by questionnaire (ever) | 267/2,625 (10.2) | 679/4,787 (14.2) | 0.05 |
| Dermatitis, eczema, rash by questionnaire | 234/2,625 (8.9) | 514/4,787 (10.7) | 0.014 | |||||||
| Wheeze by questionnaire | 275/2,625 (10.5) | 653/4,787 (13.6) | <0.001 | |||||||
| (3–19) | IgG | Allergic rhinitis by questionnaire | 62/750 (8.3) | 275/2,577 (10.7) | 0.02 | |||||
| Asthma by questionnaire (current) | 66/750 (8.8) | 253/2,577 (9.8) | 0.03 | |||||||
| Asthma by questionnaire (ever) | 98/750 (13.1) | 409/2,577 (15.9) | 0.15 | |||||||
| Allergic rhinitis and asthma (ever) | 14/750 (1.9) | 81/2,577 (3.1) | 0.99 | |||||||
| 13 | Baccioglu | 2008 | N/A | Turkey | 38.0 (17–74) | Histopathology | Skin prick test | 20/74 (27.0) | 4/16 (25.0) | 0.86 |
| Asthma by physician | 8/74 (10.8) | 5/16 (31.3) | 0.03 | |||||||
| Rhinitis | 45/74 (60.8) | 11/16 (68.8) | 0.77 | |||||||
| Urticaria | 20/74 (27.0) | 6/16 (37.5) | 0.54 | |||||||
| Food allergy | 9/74 (12.2) | 1/16 (6.3) | 0.49 | |||||||
| 14 | Fullerton | 2009 | 1991 | England | (18–71) | IgG | Skin prick test | 162/643 (25.2) | 552/1,732 (31.9) | 0.002 |
| Hay fever | 143/643 (22.2) | 455/1,732 (26.3) | 0.05 | |||||||
| Chronic bronchitis | 107/643 (16.6) | 208/1,732 (12.0) | 0.004 | |||||||
| Asthma by physician | 62/643 (9.6) | 151/1,732 (8.7) | 0.536 | |||||||
| 15 | Zevit | 2012 | 2007–2008 | Israel | (5–18) | Urea breath test | Asthma by physician | 233/3,175 (7.3) | 345/3,784 (9.1) | 0.007 |
| 16 | Karimi | 2013 | 2010–2011 | Iran | (6–12) | Urea breath test | Asthma by physician | 18/98 (18.4) | 23/98 (23.4) | 0.380 |
| 17 | Lee | 2014 | 2010–2013 | Korean | 55.4 | IgG | Asthma by questionnaire and IgE | 225/320 (70.3) | 1,159/1,794 (64.6) | 0.667 |
| 18 | Hollander | 2016 | 2002–2006 | Netherland | 6 | IgG | Wheezing by questionnaire | 18/269 (6.7) | 231/2,866 (8.1) | 0.24 |
| Asthma by questionnaire | 23/198 (11.6) | 219/2,864 (7.6) | 0.045 | |||||||
| Eczema by questionnaire | 59/610 (9.7) | 189/2,472 (7.6) | 0.25 | |||||||
| 19 | Lim | 2016 | 2011 | South Korea | ≥18 | IgG | Asthma by physician, questionnaire | 229/9,492 (2.4) | 130/5,540 (2.3) | 0.333 |
Atopy, allergy, or asthma positive/H. pylori positive;
Atopy, allergy, or asthma positive/H. pylori negative.
When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA).
Association between H. pylori and atopy, allergy, and asthma in case-control studies.
| 1 | Matricardi | 2000 | 1990–1991 | Italy | (17–24) | IgG | IgE | 35/240 (15.0) | 44/240 (18.0) | 0.325 |
| 2 | Bodner | 2000 | 1995 | Scotland | (39–45) | IgG | IgE | 77/150 (51.3) | 65/125 (52.0) | 0.991 |
| Wheeze | 49/85 (57.6) | 93/190 (48.9) | 0.229 | |||||||
| Chronic cough and phlegm | 6/19 (23.1) | 18/150 (12.0) | 0.05 | |||||||
| 3 | Tsang | 2000 | 1997–1998 | Hong Kong | 42.6 | IgG | Asthma by physician | 44/90 (48.9) | 37/97 (38.1) | 0.30 |
| 4 | Jun | 2005 | 2004–2005 | Japan | 51.2 | IgG | Asthma by physician | 10/46 (21.7) | 9/48 (18.8) | 0.917 |
| 5 | Jaber | 2006 | 2001–2003 | Saudi Arabia | 1 to ≥ 10 | IgG | Asthma by physician | 45/220 (20.4) | 128/543 (23.6) | 0.36 |
| 6 | Annagur | 2007 | 2003–2005 | Turkey | (5–15) | IgG | Asthma by physician | 20/79 (25.3) | 6/36 (16.7) | 0.227 |
| 7 | Janson | 2007 | 1990–1994 | Estonia, Iceland, Sweden | (20–44) | IgG | IgE | 81/327 (24.8) | 337/922 (36.6) | <0.001 |
| 8 | Shiotani | 2008 | 2005–2006 | Japan | 19.5 | IgG | Allergy by questionnaire | 42/369 (11.4) | 72/408 (17.6) | 0.015 |
| 9 | Reibman | 2008 | N/A | United States | (18–65) | IgG | Asthma by questionnaire | 147/318 (46.2) | 100/208 (48.1) | 0.744 |
When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA).
Association between H. pylori and atopic, allergy, and asthma in cohort studies.
| 1 | Cam | 2009 | 1999–2015 | Turkey | 14.8 | Urea breath test | Skin prick test | 15/47 (31.9) | 13/27 (48.1) | 0.215 |
| Asthma by questionnaire | 4/47 (8.5) | 1/27 (3.7) | 0.646 | |||||||
| Allergic rhinitis | 3/47 (6.4) | 1/27 (3.7) | 1.00 | |||||||
| Atopic eczema | 3/47 (6.4) | 1/27 (3.7) | 1.00 | |||||||
| 2 | Amberbir | 2011 | 2005–2009 | Ethiopia | 3.0 | Stool antigen | Self-reported wheeze | 24/80 (30.0) | 229/796 (28.8) | 0.41 |
| Self-reported eczema | 11/55 (20.0) | 242/821 (29.5) | 0.05 | |||||||
| Self-reported hay fever | 18/44 (40.9) | 235/832 (28.2) | 0.09 | |||||||
| Self-reported | 6/48 (12.5) | 247/816 (30.3) | 0.07 | |||||||
| Self-reported cockroach | 6/36 (16.7) | 247/828 (29.8) | 0.29 | |||||||
| 3 | Holster | 2012 | 1996–2004 | Netherlands | (7–9) | IgG | Wheeze by questionnaire | 12/204 (5.9) | 37/341 (10.9) | 0.05 |
| Allergic rhinitis by questionnaire | 25/294 (8.5) | 24/251 (9.6) | 0.779 | |||||||
| Atopic dermatitis by questionnaire | 21/241 (8.7) | 28/304 (9.2) | 0.960 | |||||||
| Physician-diagnosed asthma by questionnaire | 7/98 (7.1) | 42/447 (9.4) | 0.609 |
Atopy, allergy, or asthma positive/H. pylori positive;
Atopy, allergy, or asthma positive/H. pylori negative.
When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA).
Figure 1Helicobacter pylori and asthma in Indonesia. The prevalence of asthma is almost similar in Medan, Makassar, and Jakarta although the prevalence H. pylori infection is higher in Medan and Makassar than Jakarta.